MRI Screening for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
Men with a BRCA1 or BRCA2 mutation are at increased risk for early onset, aggressive prostate cancer compared to men in the general population.Standard of care screening for men with a BRCA mutation includes PSA testing and digital rectal examination (DRE), the same as with men in the general population.This study is being done to assess whether there is value in using MRI as a screening tool to detect prostate cancer at an earlier stage than may otherwise be detected using standard of care screening (PSA, DRE). It is unclear whether MRI has utility as a screening tool in this specific population at high risk for aggressive disease.
Who Is on the Research Team?
Danny J Vesprini, MD, MSc, FRCPC
Principal Investigator
Sunnybrook Health Sciences Centre
Are You a Good Fit for This Trial?
This trial is for men over 50 who are part of the Male Hereditary Cancer Research Program, have a BRCA1 or BRCA2 mutation, and can undergo an ultrasound biopsy. It's not for those with claustrophobia, MRI contraindications, contrast agent issues, or previous prostate cancer diagnosis.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
MRI Screening
Participants undergo Multispectral 3T MRI to assess its value as a screening tool for prostate cancer
Follow-up
Participants are monitored for safety and effectiveness after MRI screening
What Are the Treatments Tested in This Trial?
Interventions
- MS3TMRI
- TRUS Guided Biopsy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Toronto Sunnybrook Regional Cancer Centre
Lead Sponsor
Women's College Hospital
Collaborator
Sunnybrook Health Sciences Centre
Collaborator